Business
Alumis Presents Data Highlighting ESK-001’s Potential as a High-efficacy Oral Treatment for Systemic Lupus Erythematosus (SLE) at ACR Convergence 2024
SOUTH SAN FRANCISCO, Calif., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a clinical stage biopharmaceutical company developing oral
About this update from Alumis Inc.
[{"type":"text","content":"SOUTH SAN FRANCISCO, Calif., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a clinical stage biopharmaceutical company developing oral therapies using a precision approach to optimize clinical outcomes and significantly improve the lives of patients with immune-mediated diseases, today announced the company will give two data presentations at ACR Convergence 2024, the annual meeting of the American College of Rheumatology (ACR), being held November 14–19, 2024, in Washington, D.C. Data to be presented at ACR show that treatment with ESK-001, a highly selective allosteric oral tyrosine kinase 2 (TYK2) inhibitor, suppresses both a novel disease biomarker as well as Type 1 interferons, known key drivers of SLE. Additionally, leveraging its proprietary data analytics platform, Alumis identified novel pathways implicated in SLE that can be suppressed through TYK2 inhibition. “The ACR data show that treatment with ESK-001 downregulates key cytokines and disease biomarkers of SLE,” said Dr. Jörn Drappa, Alumis’ Chief Medical Officer. “These data, along with ESK-001’s demonstrated ability to achieve maximal TYK2 inhibition in psoriasis, suggest that ESK-001 could potentially become a high efficacy oral treatment option for patients with SLE. Our team continues to advance the Phase 2b LUMUS study in SLE, and we look forward to reporting top-line data in 2026.” Details regarding the presentations are as follows: POSTER PRESENTATION:Title: Novel Role of TYK2 mechanism in SLE Pathogenesis via T Cell and B Cell PathwaysSession Title: Genetics, Genomics & Proteomics PosterSession Type: Poster Session BDate and Time: Sunday, November 17, 2024, 10:30 a.m. – 12:30 p.m. ESTAbstract Number: 0902 POSTER PRESENTATION:Title: ESK-001, an Allosteric TYK2 Inhibitor, Maximally Suppresses Type 1 Interferon, a Therapeutic Pathway Central to SLE and CLESession Title: SLE – Treatment Poster IIISession Type: Poster Session CDate and Time: Monday, November 18, 2024, 10:30 a.m. – 12:30 p.m. ESTAbstract Number: 2434 The presentations will be available under the Publications section of the Alumis website on November 18, 2024. About SLE (Lupus) Systemic lupus erythematosus (SLE) is a chronic autoimmune disease and is the most common type of lupus. Lupus occurs when the immune system attacks its own tissues, causing inflammation, and in some cases pe...